- Home
- ERO vs VKTX Comparison
ERO vs VKTX Comparison
Compare ERO & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ERO | VKTX |
|---|---|---|
| Founded | 2016 | 2012 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.3B |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ERO | VKTX |
|---|---|---|
| Price | $30.47 | $32.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $36.50 | ★ $95.86 |
| AVG Volume (30 Days) | 1.2M | ★ 2.1M |
| Earning Date | 05-04-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $51.94 | N/A |
| Revenue Next Year | $2.43 | N/A |
| P/E Ratio | $22.61 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.79 | $22.96 |
| 52 Week High | $39.80 | $43.15 |
Technical Indicators
Market Signals| Indicator | ERO | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 59.83 | 56.83 |
| Support Level | $27.82 | $29.32 |
| Resistance Level | $32.62 | $36.56 |
| Average True Range (ATR) | 1.61 | 1.24 |
| MACD | 0.26 | 0.34 |
| Stochastic Oscillator | 67.70 | 93.00 |
Price Performance
Historical ComparisonAbout ERO Ero Copper Corp.
Ero Copper Corp is a base metals mining company. It is predominantly focused on the production and sale of copper with gold and silver produced and sold as by-products. Ero's operations are segmented between its mines in Brazil, the Caraiba Operations and the Xavantina Operations, its development project, the Tucuma Project in Brazil and corporate. Majority of its revenue is generated from its Caraiba Operations segment which consists of mining operations and processing facilities including the Pilar and Vermelhos underground mines and the Surubim open pit mine.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.